1128 related articles for article (PubMed ID: 20555147)
1. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
2. Higher cathepsin B levels in plasma in Alzheimer's disease compared to healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 22(4):1223-30. PubMed ID: 20930303
[TBL] [Abstract][Full Text] [Related]
3. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
[TBL] [Abstract][Full Text] [Related]
4. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
[TBL] [Abstract][Full Text] [Related]
5. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
[TBL] [Abstract][Full Text] [Related]
6. Biomarker profiles and their relation to clinical variables in mild cognitive impairment.
Schoonenboom SN; Visser PJ; Mulder C; Lindeboom J; Van Elk EJ; Van Kamp GJ; Scheltens PH
Neurocase; 2005 Feb; 11(1):8-13. PubMed ID: 15804919
[TBL] [Abstract][Full Text] [Related]
7. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.
Hansson O; Zetterberg H; Buchhave P; Andreasson U; Londos E; Minthon L; Blennow K
Dement Geriatr Cogn Disord; 2007; 23(5):316-20. PubMed ID: 17374949
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.
Rami L; Fortea J; Bosch B; Solé-Padullés C; Lladó A; Iranzo A; Sánchez-Valle R; Molinuevo JL
J Alzheimers Dis; 2011; 23(2):319-26. PubMed ID: 21098971
[TBL] [Abstract][Full Text] [Related]
9. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
10. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
Höglund K; Hansson O; Buchhave P; Zetterberg H; Lewczuk P; Londos E; Blennow K; Minthon L; Wiltfang J
Neurodegener Dis; 2008; 5(5):268-76. PubMed ID: 18309230
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease?
Palumbo B; Siepi D; Sabalich I; Tranfaglia C; Parnetti L
Funct Neurol; 2008; 23(2):93-6. PubMed ID: 18671910
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
13. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
Lewczuk P; Kornhuber J; Vanderstichele H; Vanmechelen E; Esselmann H; Bibl M; Wolf S; Otto M; Reulbach U; Kölsch H; Jessen F; Schröder J; Schönknecht P; Hampel H; Peters O; Weimer E; Perneczky R; Jahn H; Luckhaus C; Lamla U; Supprian T; Maler JM; Wiltfang J
Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996
[TBL] [Abstract][Full Text] [Related]
14. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.
Chiasserini D; Parnetti L; Andreasson U; Zetterberg H; Giannandrea D; Calabresi P; Blennow K
J Alzheimers Dis; 2010; 22(4):1281-8. PubMed ID: 20930282
[TBL] [Abstract][Full Text] [Related]
15. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
[TBL] [Abstract][Full Text] [Related]
16. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
Mulder SD; van der Flier WM; Verheijen JH; Mulder C; Scheltens P; Blankenstein MA; Hack CE; Veerhuis R
J Alzheimers Dis; 2010; 20(1):253-60. PubMed ID: 20164582
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
19. Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease.
Santos AN; Ewers M; Minthon L; Simm A; Silber RE; Blennow K; Prvulovic D; Hansson O; Hampel H
J Alzheimers Dis; 2012; 29(1):171-6. PubMed ID: 22214781
[TBL] [Abstract][Full Text] [Related]
20. CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age.
Kester MI; Blankenstein MA; Bouwman FH; van Elk EJ; Scheltens P; van der Flier WM
J Alzheimers Dis; 2009; 16(3):601-7. PubMed ID: 19276554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]